Fig 2. Analysis on the annualized relapse rate reduction at 2 years reported for patients with relapsing remitting multiple sclerosis included in the randomized clinical trials of Natalizumab or Fingolimod.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.